Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Perrigo Co. (PRGO) PT Raised to $93 at Cantor Fitzgerald
-
UPDATE: Cantor Fitzgerald Starts AAC Holdings (AAC) at Overweight (Earlier)
-
Cantor Fitzgerald Starts AAC Holdings (AAC) at Overweight
-
Dynavax (DVAX) Prices 5M Share Offering at $15/Sh
-
Dynavax Prices Public Offering of Common Stock
-
Orchid Island Capital Announces August 2017 Monthly Dividend and July 31, 2017 RMBS Portfolio Characteristics
-
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2017 Results
-
Dynavax (DVAX) Proposed $125M Public Offering of Common Stock
-
Dynavax Announces Proposed Public Offering of Common Stock
-
Endo International plc (ENDP) PT Lowered to $9 at Cantor Fitzgerald
-
GW Pharma (GWPH): Nearing Completion of Rolling NDA - Cantor
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2017
-
UPDATE: Cantor Fitzgerald Downgrades Zynerba Pharmaceuticals (ZYNE) to Neutral
-
Horizon Pharma (HZNP) PT Raised to $17 at Cantor Fitzgerald Following 'Beat and Raise'
-
Avino Announces US ATM Offering of up to US$25 Million
-
Streetwise Reports Examines the Uranium PEA that One Cantor Fitzgerald Analyst Says is 'the Best We Have Ever Seen'
-
Radius Health Reports Second Quarter 2017 Financial and Operating Results and Provides Business Update
-
Teva Pharma (TEVA) PT Lowered to $27 at Cantor Fitzgerald
-
Aetna (AET) PT Raised to $175 at Cantor Fitzgerald; 'Lower MLR Drives 2Q17 EPS Beat'
-
Agile Therapeutics (AGRX) Prices 5.33M Common Stock Offering at $3.75/Share
-
Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock
-
MTGE Investment (MTGE) Announces $125M ATM Offering
-
MTGE Investment Corp. Announces At The Market Offering Program of Common Stock
-
Agile Therapeutics (AGRX) Plans Offering of Common Stock
-
Agile Therapeutics Announces Proposed Offering of Common Stock
-
AxoGen, Inc. ReportsĀ 2017 Second Quarter Financial Results
-
Humana (HUM) PT Raised to $230 at Cantor Fitzgerald Following 2Q Release
-
Flex Pharma Reports Second Quarter 2017 Financial Results
-
StreetInsider.com Premium Hot Research Recap 08/01
-
Orchid Island Capital Announces Second Quarter 2017 Results
-
Cantor Fitzgerald Starts Neos Therapeutics (NEOS) at Overweight
-
Intercept Pharmaceuticals (ICPT) PT Raised to $69 at Cantor Fitzgerald; 'Can The PBC Growth Trend Persist?'
-
Arena Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Form 13F-HR CANTOR FITZGERALD INVEST For: Jun 30
-
Valeant (VRX) Formulary Changes Were Already Anticipated by Company - Cantor Fitzgerald
-
Kamada (KMDA) Prices 3.33M Public Offering at $4.50/Ordinary Share
-
Kamada Announces Pricing of Public Offering of Ordinary Shares
-
StreetInsider.com Premium Hot Research Recap 7/28
-
Cantor Fitzgerald Double Upgrades Baidu (BIDU) to Overweight
-
NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program
-
UPDATE: Cantor Fitzgerald Assumes PayPal (PYPL) at Overweight
-
Sabra Health Care REIT Files Investor Presentation
-
Kamada (KMDA) Proposed Public Offering of Ordinary Shares
-
Kamada Announces Proposed Public Offering of Ordinary Shares
-
UPDATE: Facebook (FB) PT Raised to $190 at Cantor Fitzgerald
-
Anthem (ANTM) PT Raised to $215 at Cantor Fitzgerald on 2Q Result; 'Waiting for PBM Strategy to Unfold'
-
HealthStream (HSTM) PT Lowered to $24 at Cantor Fitzgerald; Reiterates Neutral
-
Centene (CNC) PT Raised to $100 at Cantor Fitzgerald on 2Q Beat; 'Improving Visibility to Future Performance'
-
Novavax (NVAX): RSV Vaccine Improved But Proof Is Required - Cantor
-
Alphabet (GOOG) PT Raised to $1,100 at Cantor Fitzgerald

